Epidemiologic and mucosal immunologic aspects of HPV infection and HPV-related cervical neoplasia in the lower female genital tract: A review

2001 ◽  
Vol 11 (1) ◽  
pp. 9-17 ◽  
Author(s):  
M. Y. Tjiong ◽  
T. A. Out ◽  
J. Ter Schegget ◽  
M. P. M. Burger ◽  
N. Van Der Vange
Pathobiology ◽  
2020 ◽  
pp. 1-11
Author(s):  
Cristina Paula Castanheira ◽  
Mayara Luciana Sallas ◽  
Rafaella Almeida Lima Nunes ◽  
Noely Paula Cristina Lorenzi ◽  
Lara Termini

Persistent infection with some types of mucosal human papillomavirus (HPV) is the etiological factor for the development of cervical cancer and its precursor lesions. Besides, several cofactors are known to play a role in cervical disease onset and progression either by favoring or by preventing HPV infection and persistence. The microbiome of a healthy female genital tract is characterized by the presence of 1 or few varieties of lactobacilli. However, high-throughput studies addressing the bacterial diversity and abundance in the female genital tract have shown that several factors, including hormonal levels, hygiene habits, and sexually transmitted diseases may disrupt the natural balance, favoring the outgrowth of some groups of bacteria, which in turn may favor some pathological states. Recently, the vaginal microbiome has emerged as a new variable that could greatly influence the natural history of HPV infections and their clinical impact. In this context, changes in the vaginal microbiome have been detected in women infected with HPV and women with HPV-associated lesions and cancer. However, the role of specific bacteria groups in the development/progression or prevention/regression of HPV-associated pathologies is not well understood. In this review we summarize the current knowledge concerning changes in vaginal microbiome and cervical disease. We discuss the potential functional interplay between specific bacterial groups and HPV infection outcomes.


1996 ◽  
Vol 6 (1) ◽  
pp. 1-7 ◽  
Author(s):  
M. Alejo ◽  
N. Margall ◽  
X. Matias-Guiu ◽  
E. Esteva ◽  
E. Lerma ◽  
...  

2008 ◽  
Vol 4 (2) ◽  
pp. 143-150 ◽  
Author(s):  
J Matt Pearson ◽  
Richard S Feltman ◽  
Leo B Twiggs

While the majority of studies regarding the health benefits from human papillomavirus (HPV) vaccination have focused on cervical neoplasia and cancer, few have investigated how the epidemiology of vaginal and vulvar disease may be affected. To better understand how occurrence rates for vaginal and vulvar neoplasias and carcinomas may change in the future, we must have an understanding of the overall disease prevalence within a given population, the efficacy of vaccination and the proportion of cases attributable to HPV types administered in the vaccine. In this review, we will examine basic HPV epidemiology and prevalence, the molecular transformation events carried out by HPV oncoproteins, and clinical trials monitoring HPV-induced disease of the female genital tract. While precise projections of exactly how vaginal and vulvar disease prevalence will change with vaccination will require more studies, the preliminary data are promising.


Sign in / Sign up

Export Citation Format

Share Document